Switching patients from IV to pill form of drugs could save millions

(Medical Xpress) -- Switching hospitalized patients able to take medication by mouth from intravenous to pill forms of the same drugs could safely save millions of dollars a year, new Johns Hopkins research suggests.

In a review of computerized records for the year 2010, conducted at The Johns Hopkins Hospital in Baltimore, the researchers estimated savings of more than $1.1 million in the Department of Medicine alone — not including surgical patients — by swapping out four commonly prescribed IV medications with their oral equivalents. A report on the study is published in the journal Clinical Therapeutics.

“Our study looked at just four drugs administered by one department in one hospital in one year and found more than a million dollars in potential savings,” says Brandyn D. Lau, a medical informatics specialist at the Johns Hopkins University School of Medicine and the study’s leader. “Imagine if every hospital took a hard look at substituting oral medications for IV ones whenever possible. We’re talking about an enormous financial impact, with no risk to patients.”

According to the Centers for Medicare and Medicaid Services, roughly 12 percent of U.S. health care expenditures in 2009 — $293.2 billion — were for medications and nondurable medical products.

Lau says a large-scale switch to oral medications has the potential to not only decrease costs, but also to reduce the need for puncturing veins to insert intravenous tubes or medications directly, procedures that carry a higher risk of hospital-acquired bloodstream infections, and longer hospital stays. Simple reminders to physicians that their patients may be eligible to switch medication types could yield large savings, the researchers say.

The four medications reviewed in the study were chlorothiazide (a medication used to treat high blood pressure and address fluid retention), voriconazole (an anti-fungal), levetiracetam (to stop seizures) and pantoprazole (for acid reflux). By combing Hopkins’ computerized provider order entry (COPE) system, they examined whether patients receiving these drugs intravenously were also prescribed other medications orally or if they were being fed solid meals, another indication that they would likely be able to swallow pills. In 2010, a total of 10,905 doses of the four medications were given by IV to patients admitted through the Department of Medicine. Lau says the drugs are given even more frequently in surgery patients.

The team compared those results with the cost of the various medications. For example, the wholesale cost of a 5-milligram tablet of chlorothiazide is $1.48. An equivalent dose of the drug given intravenously is $357.24, more than 200 times as much as the oral version. Pantoprazole, the most commonly administered medication in the study, is $4.09 per 40-milligram tablet, while a 40-milligram vial is $144. That medication is often given to patients several times a day. The potential cost savings per patient for the acid reflux medication would be $680.98, the researchers found.

The researchers note that not all patients are able to switch from the IV form to the oral form of a . Diet orders may change, Lau says, or a physician may have a reason for not switching a particular patient to an oral medication. But even a small increase in the conversion of patients from IV to oral medication would have a substantial financial impact due to the considerable difference in costs between the two forms. Meanwhile, though Lau’s research only looked at the wholesale costs of the drugs, there are other costs associated with giving medication by IV that could be reduced if fewer drugs were administered that way, he says.

The researchers chose these four drugs to study because the oral and IV forms are very similar to one another, but many other drugs potentially could also be swapped out for an even greater cost savings.

To implement the swaps, Lau says hospitals with computerized medication systems could add alerts to their programs that would appear when a patient on an IV medication meets eligibility criteria for oral medication intake. Lau cautions, however, that doctors are already bombarded with reminders and it might be best to start with drugs with the highest savings per dose, such as levetiracetam and chlorothiazide.

“There is a danger in over-reminding,” Lau says. “Constant reminders may annoy doctors to the point where they stop paying attention. We need to study the best way to get doctors to switch from IV to oral medications.”

Education, he says, is another avenue. Teaching doctors that is a cheaper alternative to IV may encourage them to make the switch without subjecting them to regular, potentially irritating reminders.

add to favorites email to friend print save as pdf

Related Stories

Can text messaging improve medication adherence?

May 24, 2011

Text messaging and adolescents don’t always mix well, but researchers at National Jewish Health hope text messages can spur teenagers to take their asthma medications more reliably. The study is testing whether health ...

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

Oct 24, 2014

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments